ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1556

Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)

Ines Perez - Sancristobal1, Dalifer Freites1, Leticia Lopez Pedraza2, Maria Paula Alvarez Hernandez1, Jose Ignacio Colomer3, Alfredo Madrid - Garcia2, Benjamin Fernandez1, Cristina Vadillo1, Luis Rodriguez Rodriguez4, Arkaitz Mucientes2, Leticia Leon - Mateos2 and Lydia Abasolo5, 1Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, 2Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, 3Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, 4Hospital Clinico San Carlos, Madrid, Spain, 5Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain

Meeting: ACR Convergence 2021

Keywords: COVID-19, Epidemiology, Infection, Miscellaneous Rheumatic and Inflammatory Diseases, Mortality

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Session Title: Infection-related Rheumatic Disease Poster (1530–1564)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related to COVID-19; and b) to analyze the role of RMDs in mortality risk.

Methods: An observational longitudinal study was conducted during the epidemic peak in Madrid (1stMar to 20thMay2020). All patients attended at the rheumatology outpatient clinic of a tertiary hospital with a diagnosis of RMDs and SARS – CoV 2 infection were included (according to a medical diagnosis or confirmed with a positive SARS-CoV-2 PCR diagnostic test). Main outcome: death related to COVID-19 infection. Independent variable: type of RMDs including: autoimmune (systemic autoimmune conditions (SAC) and inflammatory joint disease (IJD)) and non–autoimmune (mechanical diseases and inflammatory diseases (microcrystalline arthritis and tendonitis)). Covariates: sociodemographic, comorbidities, treatment for the RMDs.

Survival techniques were used to estimate the MR related to COVID-19, given per 1,000 persons-month with a 95% confidence interval [CI]. The time of observation comprised the elapsed time between the date of COVID-19 diagnosis of infection until the date of patient’s death, or end of study. Cox multiple regression analysis was run to examine the effect of autoimmune RMDs compared to non-autoimmune RMDs on mortality risk adjusted by sex, age and comorbidities. Results were expressed by Hazard Ratio (HR) and [CI].

Results: 405 patients were included with RMD and COVID – 19 infection with a total follow-up 642.57 patients-month. 69.14 % were women with a mean age at diagnosis of 59.37 ± 15.26 years. The evolution time from the diagnosis of rheumatic disease was 7.62 ± 8.39 years. Of the 405 patients, 243 (60%) had non-autoimmune RMD and 162 (39.9%) (106 (65.43%) IJD, 56 (34.56%) systemic condition) had autoimmune RMD. Of the 405 patients, 44 (11%) died during the follow-up, being 12± 14 days the mean time from infection to death (P50: 6[2-12] and a maximum of 60 days). MR was estimated in 68.48 [50.96-92.01] per 1,000 persons-month. CMR was higher for men (MR 105.45 [68.03-163.45]) than for women (MR 52.99 [35.52-79.06]) and in older people (MR < 60: 4.47, [0.67-31.70]; MR 60-75 years: 32.28 [13.44-77.55]; MR >75Years: 487.18 [354.49-669.53]). The HR of mortality in autoimmune RMDs compared to non-autoimmune RMDs did not achieved statistical significance (HR: 1.39 [0.77-2.5], p=0.27). After adjusting for confounders, we did not find higher risk of mortality among the different types of RMDs (HR autoimmune vs non-autoinmunes: HR: 1.12 [0.6-2.02], p=0.7; HR IJD vs SAC; 1.42 [0.58-3.48], p=0.441; HR non-autoimmune vs SAC: 1.19 [0.52-2.68], P=0.677). Age (HR: 1.13; [1.10-1.15], p< 0.001), and the presence of comorbidities (HR: 2.43; [1.16-4.15], p=0.015) increased the Mortality risk.

Conclusion: In patients with RMD and COVID-19 infection, we found a mortality rate of 68.5 per 1000 persons-month. This study shows that the mortality risk related to COVID-19 is similar between autoimmune and non-autoimmune diseases after adjusting by confounders. We also found that age and comorbidities are risk factors for mortality related to COVID-19 infection.


Disclosures: I. Perez - Sancristobal, None; D. Freites, None; L. Lopez Pedraza, None; M. Alvarez Hernandez, None; J. Colomer, None; A. Madrid - Garcia, None; B. Fernandez, None; C. Vadillo, None; L. Rodriguez Rodriguez, None; A. Mucientes, None; L. Leon - Mateos, None; L. Abasolo, None.

To cite this abstract in AMA style:

Perez - Sancristobal I, Freites D, Lopez Pedraza L, Alvarez Hernandez M, Colomer J, Madrid - Garcia A, Fernandez B, Vadillo C, Rodriguez Rodriguez L, Mucientes A, Leon - Mateos L, Abasolo L. Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/mortality-rate-related-to-covid-19-in-rheumatic-and-musculoskeletal-diseases-rmds/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-rate-related-to-covid-19-in-rheumatic-and-musculoskeletal-diseases-rmds/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences